Mylan Calls Apotex's Suit A Bid To Destroy Exclusivity Rights
Mylan Pharmaceuticals Inc. sought to intervene in Apotex Inc.'s suit for a declaration of noninfringement of Daiichi Sankyo Inc.'s Benicar HCT patent, saying Wednesday that Apotex is merely trying to "destroy"...To view the full article, register now.
Already a subscriber? Click here to view full article